» Articles » PMID: 32238757

Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)

Overview
Date 2020 Apr 3
PMID 32238757
Citations 448
Authors
Affiliations
Soon will be listed here.
Abstract

Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19.

Citing Articles

Unveiling the antiviral inhibitory activity of ebselen and ebsulfur derivatives on SARS-CoV-2 using machine learning-based QSAR, LB-PaCS-MD, and experimental assay.

Sinsulpsiri S, Nishii Y, Xu-Xu Q, Miura M, Wilasluck P, Salamteh K Sci Rep. 2025; 15(1):6956.

PMID: 40011571 PMC: 11865625. DOI: 10.1038/s41598-025-91235-1.


The Evaluation of Oral Health in Patients Undergoing Dental Treatment During the COVID-19 Pandemic.

Bielecki-Kowalski B, Kowalczyk O, Podziewska M, Agier P, Kroc-Szczepkowska A, Kozakiewicz M J Clin Med. 2024; 13(23).

PMID: 39685681 PMC: 11642660. DOI: 10.3390/jcm13237216.


Prophylactic and therapeutic vaccine development: advancements and challenges.

Weerarathna I, Doelakeh E, Kiwanuka L, Kumar P, Arora S Mol Biomed. 2024; 5(1):57.

PMID: 39527305 PMC: 11554974. DOI: 10.1186/s43556-024-00222-x.


Impact of Spa Therapy on Symptoms and Quality of Life in Post-COVID-19 Patients with Chronic Conditions.

Costantino M, Giudice V, Farroni M, Marongiu F, De Caro F, Filippelli A J Clin Med. 2024; 13(17).

PMID: 39274303 PMC: 11396595. DOI: 10.3390/jcm13175091.


Score of fear of COVID-19 and physical activity level are related to the habitual consumption of dietary supplements.

Tavares da Silva W, Castelo P, Pereira L, Pardi V, Murata R, Andrade E PLoS One. 2024; 19(9):e0307870.

PMID: 39241015 PMC: 11379318. DOI: 10.1371/journal.pone.0307870.


References
1.
Cyranoski D . Did pangolins spread the China coronavirus to people?. Nature. 2021; . DOI: 10.1038/d41586-020-00364-2. View

2.
Willman M, Kobasa D, Kindrachuk J . A Comparative Analysis of Factors Influencing Two Outbreaks of Middle Eastern Respiratory Syndrome (MERS) in Saudi Arabia and South Korea. Viruses. 2019; 11(12). PMC: 6950189. DOI: 10.3390/v11121119. View

3.
Mulangu S, Dodd L, Davey Jr R, Mbaya O, Proschan M, Mukadi D . A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019; 381(24):2293-2303. PMC: 10680050. DOI: 10.1056/NEJMoa1910993. View

4.
Okba N, Raj V, Haagmans B . Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. Curr Opin Virol. 2017; 23:49-58. PMC: 7102752. DOI: 10.1016/j.coviro.2017.03.007. View

5.
Loset G, Roux K, Zhu P, Michaelsen T, Sandlie I . Differential segmental flexibility and reach dictate the antigen binding mode of chimeric IgD and IgM: implications for the function of the B cell receptor. J Immunol. 2004; 172(5):2925-34. DOI: 10.4049/jimmunol.172.5.2925. View